36 completed, 7 unknown, 4 recruiting, 3 not yet recruiting. 57 Phase 1, 14 Phase 2.
Follow Capsules: new trials by email Literature Review of Capsules trials Research Report on Capsules
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response Lithium orotate, Matched Placebo (Capsules) - Alzheimer s Disease | Phase 1 / Phase 2 | Not yet recruiting | Johns Hopkins University | 40 | 2026-12-01 | 2026-10-07 |
| Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease | Phase 1 / Phase 2 | Recruiting | Atavistik Bio, Inc | 100 | 2026-07-27 | 2026-11-06 |
| Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules - Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP) | Phase 1 | Active not recruiting | Oscotec Inc. | 48 | 2026-07-10 | 2026-09-01 |
| Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial Fecal Microbiota Transplantation (FMT) Capsules, Placebo capsules - Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Heart Failure | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital of Air Force Medicial University | 50 | 2026-06-01 | 2026-06-05 |
| Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions. Ingavirin forte, capsules, 90 mg + 20 mg, Ingavirin, capsules, 90 mg - Influenza, Acute Respiratory Viral Infections | Phase 1 | Recruiting | Valenta Pharm JSC | 36 | 2025-07-11 | 2026-06-12 |
| Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd. - Pruritus | Phase 1 | Not yet recruiting | Rabin Medical Center | 30 | 2025-05-30 | 2025-04-17 |
| L-Citrulline and Endothelial Function L-Citrulline, capsule - Aging | Phase 1 | Completed | University of Oklahoma | 20 | 2024-01-03 | 2026-03-12 |
| A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo - Healthy Volunteers | Phase 1 | Unknown | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 70 | 2023-10-02 | 2024-02-15 |
| A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients LTI-03, Placebo - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Rein Therapeutics | 24 | 2023-07-06 | 2025-07-31 |
| Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2). LQT-1213, Placebo, Dofetilide 250 μg Cap - Long QT Syndrome | Phase 1 / Phase 2 | Terminated | Thryv Therapeutics, Inc. | 42 | 2023-03-12 | 2025-07-24 |
| Effect of Supplementation With Anthocyanins on Iron Metabolism in Female Swimmers Black chokeberry extract in capsules with 18% standardization of the anthocyanins content, Chokeberry fiber in capsules - Iron Deficiencies, Inflammation | Phase 1 / Phase 2 | Completed | Poznan University of Physical Education | 22 | 2023-03-01 | 2024-07-03 |
| Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease Intestinal Microbiota Transplant (IMT) Capsules, Placebo Capsules - Liver Disease; Alcohol-Related, Cirrhosis | Phase 1 / Phase 2 | Active not recruiting | Virginia Commonwealth University | 80 | 2022-11-21 | 2026-08-24 |
| Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities Nabilone - Intellectual Disability, Developmental Disability | Phase 1 | Completed | Hsiang-Yuan Lin | 20 | 2022-03-17 | 2026-01-23 |
| The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions Aviga, capsules 50 mg / Sutent®, capsules 50 mg, Sutent®, capsules 50 mg / Aviga, capsules 50 mg - Bioequivalence | Phase 1 | Unknown | JLLC NatiVita | 22 | 2022-01-21 | 2022-02-01 |
| A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer Veliparib, capsule, Veliparib, tablet, Carboplatin - Cancer - Ovarian | Phase 1 | Withdrawn | AbbVie | 2021-11-15 | 2021-12-08 | |
| Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects. Dexlansoprazole - Healthy, Bioequivalence Study | Phase 1 | Completed | University of Karachi | 60 | 2021-09-18 | 2023-11-29 |
| A Study to Investigate the Effect of Food on the Pharmacokinetics of IN-A002 Capsule in Healthy Male Subjects IN-A002(IN-115314) capsule - Healthy | Phase 1 | Unknown | HK inno.N Corporation | 12 | 2021-08-13 | 2021-08-25 |
| Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD) - Driving Behavior, Driving Under the Influence | Phase 1 | Completed | Timothy L. Brown | 13 | 2021-07-16 | 2023-07-25 |
| 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546 EXS21546 Powder for Oral Suspension, EXS21546 Granule in Capsule, Midazolam - Oncology | Phase 1 | Completed | Exscientia AI Limited | 64 | 2020-12-08 | 2022-05-16 |
| Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up. Low dose tadalafil 5 mg, Tolterodine 4 Mg Oral Capsule, Extended Release, Placebo - Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence | Phase 1 | Completed | Kasr El Aini Hospital | 90 | 2020-12-01 | 2022-08-15 |
Showing 20 of 57. Sign in to see all of them.
Neoplasms (3) · Inflammation (2) · Substance-Related Disorders (2) · Aggression (1) · Alcoholism (1) · Arteriovenous Malformations (1) · Arthritis, Rheumatoid (1) · Asthma (1) · Attention Deficit Disorder with Hyperactivity (1) · Autoimmune Diseases (1) · Bacterial Infections (1) · COVID-19 (1) · Cardiomyopathy, Hypertrophic (1) · Cardiovascular Diseases (1) · Colonic Neoplasms (1)
Actavis Inc. (4) · AstraZeneca (2) · Genentech, Inc. (2) · Mylan Pharmaceuticals Inc (2) · AbbVie (1) · Ahmed A. H. Abdellatif (1) · Andrew Slivka (1) · Atavistik Bio, Inc (1) · Boehringer Ingelheim (1) · Cingulate Therapeutics (1) · Cytokinetics (1) · Daiichi Sankyo (1) · Debiopharm International SA (1) · Dwight Koeberl, M.D., Ph.D. (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)
United States (28) · United Kingdom (6) · South Korea (5) · Canada (4) · China (3) · Australia (2) · Belgium (2) · Egypt (2) · France (2) · Germany (2) · Italy (2) · Pakistan (2) · Spain (2) · Taiwan (2) · Argentina (1)
Daniel V. Freeland, DO (2) · Gaetano Morelli, M.D. (2) · James P. Doherty, DO (2) · Andriy Yabluchanskiy, MD, PhD (1) · Christopher Morrow, MD, MHS (1) · Dwight D Koeberl, MD, PhD (1) · Erik Brouwer, MD (1) · Frederick Wittke, MD (1) · Grant Bochicchio, MD, MPH (1)
PMID 25467588, PMID 27032509, PMID 29881409, PMID 30025991, PMID 30869182, PMID 30937899, PMID 31740368, PMID 32863171, PMID 33568226, PMID 34471960, PMID 34814185, PMID 35045888, PMID 35127778, PMID 36061336, PMID 39929221, PMID 42518155, PMID 42538332
2018 (2), 2015 (1), 2023 (1), R01AA029398 (1), R21AT002073 (1), ZIAHD000641-23 (1)